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Abstract
Objective—To explore the effectiveness of raltegravir-based antiretroviral therapy (ART) on 
treatment response among ART-naive patients seeking routine clinical care.
Design—Cohort study of adults enrolled in HIV care in the United States.
Methods—We compared virologic suppression and CD4 cell count recovery over a 2.5 year 
period after initiation of an ART regimen containing raltegravir or efavirenz using observational 
data from a US clinical cohort, generalized to the US population of people with diagnosed HIV. 
We accounted for nonrandom treatment assignment, informative censoring, and nonrandom 
selection from the US target population using inverse probability weights.
Results—Of the 2843 patients included in the study, 2476 initiated the efavirenz-containing 
regimen and 367 initiated the raltegravir-containing regimen. In the weighted intent-to-treat 
analysis, patients spent an average of 74 (95% CI: 41, 106) additional days alive with a suppressed 
Correspondence: Jessie K. Edwards, 135 Dauer Dr., 2101 McGavran-Greenberg Hall, CB 7435, University of North Carolina at 
Chapel Hill, Chapel Hill, NC 27599, jessedwards@unc.edu, Phone: 919-966-7438. 
Roles of authors: JKE, SRC, HIH, and JJE designed the study. RDM, WCM, JJE, SRC and MJM played a role in development of the 
CNICS cohort. JKE drafted the manuscript. All authors revised the manuscript.
HHS Public Access
Author manuscript
AIDS. Author manuscript; available in PMC 2019 January 14.
Published in final edited form as:













viral load on the raltegravir regimen than on the efavirenz regimen over the 2.5-year study period. 
CD4 cell count recovery was also superior under the raltegravir regimen.
Conclusions—Patients receiving raltegravir spent more time alive and suppressed than patients 
receiving efavirenz, but the probability of viral suppression by 2.5 years after treatment was 
similar between groups. Optimizing the amount of time spent in a state of viral suppression is 
important to improve survival among people living with HIV and to reduce onward transmission.
Keywords
HIV; HIV integrase inhibitors; efavirenz; viral load; sustained virologic response
Introduction
Integrase inhibitors have expanded first-line treatment options for people living with HIV. 
Randomized trials have demonstrated that patients initiating regimens containing integrase 
inhibitors experience more rapid plasma HIV RNA suppression following treatment 
initiation and fewer adverse events than patients initiating other first-line regimens [1–9]. 
Furthermore, addition of an integrase inhibitor to an initial treatment regimen improves 
tolerability for patients with treatment-limiting toxicity with reverse transcriptase or protease 
inhibitors [10] and increases treatment efficacy for patients with prior treatment failure 
[7,11–14].
For these reasons, many patients new to antiretroviral therapy (ART) have initiated regimens 
containing integrase inhibitors since the first drug in this class, raltegravir, was approved on 
October 12, 2007. Here, we use observational data on ART-naïve patients from the Centers 
for AIDS Research Network of Integrated Clinical Systems (CNICS) to compare virologic 
suppression [15,16] and CD4 cell count recovery over 30 months after initiation of an ART 
regimen containing raltegravir in combination with tenofovir disoproxil fumarate (TDF)/
emtricitabine (FTC) with a regimen containing efavirenz plus the same reverse transcriptase 
inhibitor backbone. We account for differences in patient characteristics between treatment 
groups (i.e., channeling bias) and between patients in CNICS and the population of people 
with diagnosed HIV in the US (lack of generalizability) using inverse probability weighting. 
Examining the immunologic trajectories of patients in an observational clinical setting 
reflects the performance of these regimens in clinical care, free from Hawthorne effects and 
selective enrollment into a trial population.
Methods
Study sample
Patients with a detectable viral load who initiated an antiretroviral therapy regimen 
containing TDF and FTC plus raltegravir or efavirenz at a CNICS site between 12 October 
2007 and 31 December 2014 and had not previously initiated combination antiretroviral 
therapy, defined as treatment with 3 or more antiretroviral drugs, were eligible for inclusion 
in this analysis (N = 3060). Patients were excluded if they were missing information on 
transmission risk factor, race, sex, or baseline CD4 cell count (n = 217), leaving 2843 
patients in the cohort.
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Patients were followed from initiation of one of the regimens of interest until death, loss to 
follow-up, or administrative censoring at 2.5 years (30 months) after study entry or on 
December 31, 2014. Patients were considered to be lost to follow-up after 12 months 
without a documented clinic visit in which CD4 cell count or viral load was measured. Each 
CNICS site semiannually queries the United States Social Security Death Index and/or 
National Death Index to confirm reported deaths and record deaths not captured by the sites. 
Viral loads and CD4 cell counts were collected during the course of routine HIV care at each 
CNICS site.
We present results of both an intent-to-treat analysis, in which patients remained in their 
initial treatment group regardless of whether or not they later switched regimens, and a per 
protocol analysis, in which patients were censored at any change in treatment regimen, with 
2 exceptions: 1) changes from the raltegravir regimen to another integrase inhibitor–based 
regimen (including fixed-dose combination of elvitegravir, cobicistat, TDF, and FTC or 
dolutegravir, TDF, and FTC; and 2) changes from the efavirenz regimen to the 
nonnucleoside reverse transcriptase inhibitor regimen of rilpivirine, TDF, and FTC.
Institutional review boards at each site approved CNICS study protocols, and patients 
provided written informed consent to be included in the CNICS cohort or contributed 
administrative and/or clinical data with a waiver of written informed consent where 
approved by local institutional review boards.
Target population
Results were generalized to a target population defined by all people with diagnosed HIV in 
the US between 2008 and 2014 to extrapolate study findings to the larger population of 
people living with HIV in the United States. Characteristics of this population, including 
race/ethnicity, sex, age group, and likely mode of transmission (i.e., male-to-male sexual 
contact, injection drug use) were provided by the Centers for Disease Control and 
Prevention from national HIV surveillance data [17,18].
Statistical methods
We compared the proportion of patients alive and virally suppressed and the mean CD4 cell 
count improvement over 30 months after ART initiation between patients initially prescribed 
the raltegravir and efavirenz regimens. We estimated the difference in CD4 cell count 
recovery between treatment groups by comparing the mean CD4 cell count at baseline to the 
mean CD4 cell count 30 months later in each treatment group. The proportion of patients 
alive and suppressed at each time point was estimated using the method formally described 
by Gouskova et al [15,19], adapted to account for nonrandom treatment assignment and the 
competing event of death, and the 30-month restricted mean time alive and suppressed was 
the sum of this proportion over the 30-month follow-up period.
We accounted for differences between patients in the study sample and the US population of 
people with diagnosed HIV, differences in baseline characteristics between patients 
prescribed each regimen, and informative censoring due to loss to follow-up or regimen 
switching using inverse probability weights. Technical details can be found in Appendix 1.
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Of the 2843 patients included in the study, 2476 initiated the efavirenz-containing regimen 
and 367 initiated the raltegravir-containing regimen (Table 1). In the intent-to-treat analysis 
weighted to account for sampling, nonrandom treatment assignment, and informative 
censoring, patients initiating efavirenz spent an average of 556 days of the 913-day study 
period alive and suppressed, while patients initiating raltegravir spent an average of 630 days 
in this state, for a difference of 74 (95% CI: 41, 106) days in favor of raltegravir. This 
difference in time suppressed is primarily driven by more rapid suppression under raltegravir 
than efavirenz. The probability of being alive and suppressed after 2 years was similar in the 
efavirenz group (70.3%) and in the raltegravir group (71.5%) (Figure 1). The advantage of 
raltegravir in terms of number of days virally suppressed was even greater in the “per 
protocol” analysis, in which patients were censored at a change in regimen (difference: 80 
days; 95% CI: 50, 117).
CD4 cell count improved over time from treatment initiation for both groups. In the 
weighted intent-to-treat analysis, CD4 cell count improvement over the 30-month period 
was 215 cells/mm3 for the efavirenz group and 247 cells/mm3 for raltegravir group, for a 
difference of 32 (95% CI: 14, 49) cells/mm3 in favor of raltegravir. Results were similar in 
the per protocol analysis (difference: 30 cells/mm3; 95% CI: 3, 57). Full tabular and 
graphical results are presented in Appendix 2.
Discussion
Patients receiving raltegravir had a modest advantage in terms of the mean time spent alive 
and virally suppressed over patients receiving efavirenz during the 30-month period 
following treatment initiation. As might be expected, this advantage was driven by initial 
viral suppression; patients initiating the raltegravir regimen experienced a shorter time to a 
measured viral load under 50 copies/mL than patients receiving efavirenz. The clinical 
impact of the difference in days suppressed for an individual patient is uncertain, but this 
difference may have an impact on onward transmission. In addition, reducing viral burden 
over time may play a role in reducing HIV-related inflammation [20,21] and other negative 
effects of chronic HIV infection [22–24].
Our result that patients initiating raltegravir experienced more rapid viral suppression than 
patients initiating efavirenz aligns with findings from randomized trials comparing efavirenz 
and raltegravir [1,25]. In the STARTMRK trial, long-term viral suppression over 5 years 
appeared to be superior in the raltegravir arm than the efavirenz arm, though much of this 
difference was due to treatment discontinuation in the efavirenz arm, which was treated as 
virologic failure [26]. The difference in CD4 cell count improvement was similar between 
this study (30 cells/mm3 over approximately 130 weeks) and the STARTMRK trial (37 
cells/mm3 over 156 weeks) [27], though participants in STARTMRK who changed therapy, 
had virologic rebound, or experienced intolerance were discontinued from study, which may 
have influenced CD4 response results. The clinical benefits of relatively small but significant 
differences in CD4 cell response are unknown in the context of long-term (decades) 
antiretroviral therapy.
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The current study complements the results from randomized trials. Here, we estimated that 
raltegravir was associated with superior viral suppression among patients in routine care 
settings under real-world adherence patterns, despite its higher pill burden. Even trials 
reporting results from intent-to-treat analyses, which typically do not account for 
nonadherence, are subject to Hawthorne effects in which participants may display different 
adherence patterns than they would under real world conditions. Accordingly, these trials 
may over- or underestimate the effectiveness of a given treatment regimen in routine clinical 
care [28]. In addition, results from this study in the CNICS cohort were generalized to the 
US population of people with diagnosed HIV to provide a population-level estimate of 
observed study effects [29]. Finally, because regimen switches for reasons other than 
virologic failure (e.g., tolerability, toxicity, or convenience) are increasingly common [30], 
we did not consider regimen switch to be virologic failure.
The potential for regimen switches in the context of routine care may explain why the 
estimated effect of raltegravir in the intent-to-treat analysis appeared to be attenuated 
compared with results from STARTMRK. For example, in the intent-to-treat analysis, 
positive results from patients who switched from efavirenz to an alternative therapy for 
reasons of toxicity or tolerability would be seen as beneficial outcomes for initial 
prescription of efavirenz. Therefore, these results may show efavirenz to perform better than 
it appeared to perform in trials that treated regimen switch as virologic failure. In addition, 
initiating therapy with a regimen that had sub-optimal outcomes in clinical trials may have 
improved outcomes in clinical practice, where switching therapy is frequently used to 
manage even mild or moderate adverse events. Such frequent switching may result in a 
smaller clinical impact of the initial therapy choice than seen in trials that treat regimen 
switching as failure. Switching therapy for intolerance has little clinical impact provided the 
switch is not accompanied by rebound in plasma HIV RNA, which carries a resistance risk 
that can be considered a life-long adverse event. Appendix 3 reports counts of patients in 
each arm who switched regimens. As expected, the estimated benefit of the raltegravir 
regimen in terms of number of days suppressed was greater when patients were censored at 
these changes in treatment regimen in the per-protocol analysis than in the intent-to-treat 
analysis.
In this study, patients receiving raltegravir spent more days alive and virally suppressed and 
had superior CD4 cell count recovery than patients receiving efavirenz over the 30 months 
following treatment initiation. Optimizing the amount of time spent in a state of viral 
suppression is important when considering antiretroviral treatment plans not only to improve 
survival among people living with HIV [31] but also to reduce onward transmission from 
people living with HIV to their HIV-uninfected partners [32–34].
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Appendix 1. Technical details
The date of initial viral suppression was the midpoint between the first viral load 
measurement under 50 copies/mL and the previous viral load measurement. The date of 
subsequent viral rebound was defined as the midpoint between the date of the first of 2 viral 
load measurements over 200 copies/mL and the previous viral load measurement [21].
The proportion suppressed in treatment group x at time t, Gx(t), was the proportion of 
patients who had initially suppressed their viral loads following treatment by time t and had 
not yet experienced viral rebound or death following initial viral suppression, or 
, where  is the Aalen-Johansen estimate [23] of the risk 
of initial viral suppression following treatment initiation,  is the estimate of the risk of 
viral rebound following initial suppression, and  is the risk of death following initial 
viral suppression.
We also compared the 30-month restricted mean time alive and suppressed for each 
treatment group. The restricted mean time suppressed, Ax(τ), was the sum over follow-up 
time τ of the probability of being suppressed and alive at each time point, or 
, where t indexes days since treatment initiation.
To estimate the differences in CD4 cell count improvement and proportion with viral 
suppression under each treatment plan, we made several assumptions. First, we assumed that 
patients receiving raltegravir were exchangeable with patients receiving efavirenz, 
conditional on a set of measured baseline characteristics, including age, sex, black race vs. 
other, transmission risk factors (indicators for history of injection drug use and being a man 
who has sex with men), baseline CD4 cell count, prior AIDS diagnosis, history of 
depression and anxiety at baseline, and year of study entry. We accounted for differences in 
these patient characteristics between treatment groups using inverse probability of treatment 
weights. Treatment weights for each patient were the inverse probability of being assigned to 
raltegravir (rather than efavirenz) conditional on covariates L, or Wx = f{X}/f{X|L}, where 
f{X} is the density of X evaluated at the observed value.
Because raltegravir was introduced in 2012 and its use increased over time, some of the 
apparent beneficial effect of raltegravir could have been due to improvements in clinical care 
that occurred concurrent with the increase in popularity of raltegravir. We accounted for this 
possible confounding by calendar period by including the year of CNICS enrollment in the 
treatment weights. However, confounding bias by date of study entry could remain after 
accounting for year of study entry if, within each year, later calendar dates were associated 
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with both an increase probability of raltegravir use and improved outcomes due to other 
improvements in clinical care.
Second, we assumed that patients in the study at time t were exchangeable with patients who 
were lost to follow-up at time t, conditional on the set of the measured time-fixed variables 
listed above and time-varying patient characteristics, including CD4 cell count, viral load, 
and history of AIDS diagnosis at the previous visit. We accounted for differences in these 
characteristics between patients remaining under observation and patients who had dropped 
out of the study using inverse probability of censoring weights [35]. Censoring weights for 
each person month were the inverse probability of having recorded data for CD4 cell count 
or viral load at time t, conditional on time-fixed and time-varying covariates Z(t), or Wc(t) = 
P{C̄(t) = 0}/P{C̄(t) = 0|X = x, Z(t) = z(t)}, where C̄(t) = 0 indicates that the patient remained 
in the study through time t.
Third, we accounted for differences between people initiating one of the two regimens of 
interest in CNICS and the target population of people with diagnosed HIV in the United 
States using inverse odds of sampling weights [36]. Sampling weights were estimated as WS 
= P(S = 0|V = v)/P(S = 1|V = v), where S is an indicator of being included in the study (Si = 
1) or the target population (Si = 0), and Vi is a vector of covariates that differ between the 
sample and target population (here: sex, race, transmission risk factor, age, and year of study 
entry).
The numerator and denominator of the 3 sets of weights were estimated using logistic 
regression. The final weights for each person-month W(t) were a product of the time-fixed 
sampling and exposure weights and the time-varying censoring weights.
When using the inverse probability weights, we assumed that patients had nonzero 
probability of sampling, being assigned to each treatment arm, and remaining in the study 
through time t, conditional on measured covariates. In addition, we assumed that parametric 
models for the weights were correctly specified; to improve the flexibility of the parametric 
models, we modeled all continuous covariates using restricted quadratic splines [37]. 
Finally, we assumed that all variables (treatment regimens, viral suppression, CD4 cell 
count, and covariates) were measured without error.
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Appendix 2. Full tabular and graphical results
Table A1
Outcomes related to viral suppression and death among 2843 patients who initiated an 
antiretroviral therapy regimen containing efavirenz or raltegravir in combination with 
tenofovir DF/emtricitabine at a CNICS site between October 12, 2007 and December 31, 
2014 at 8 US clinical sites, followed over 30 months after treatment initiation, generalized to 
the US population of people with HIV diagnosed between 2008 and 2014
Crude Weighted a







Deaths Days alive 
& 
suppressed




Intent to treat analysis b
Efavirenz 2476 1929 196 46 561 0 556 0
Raltegravir 367 315 35 12 660 99 (71, 127) 630 74 (41, 106)
Per protocol analysis c
Efavirenz 2476 1669 134 31 555 0 543 0
Raltegravir 367 302 29 9 663 109 (80, 137) 626 83 (50, 117)
CNICS: Centers for AIDS Research Network of Integrated Clinical Systems
a
Weights were the product of sampling weights (to account for differences in patient characteristics between the study 
population and the US population of people diagnosed with HIV), treatment weights (to account for differences in patient 
characteristics between treatment groups), and censoring weights (to account for differences in time-fixed and time-varying 
characteristics between those censored and those remaining in the study).
b
The intent to treat analysis followed patients from treatment assignment until death, loss to follow-up, or administrative 
censoring.
c
The per protocol analysis censored patients when they changed treatment regimens
Table A2
CD4 cell count at treatment initiation and 30 months later among 2843 patients who initiated 
an antiretroviral therapy regimen containing efavirenz or raltegravir in combination with 
tenofovir DF/emtricitabine at a CNICS site between October 12, 2007 and December 31, 
2014 at 8 US clinical sites, generalized to the US population of people with HIV diagnosed 
between 2008 and 2014
Treatment n Mean CD4 cell 
count at treatment 
initiation
Mean CD4 cell count 
at 30 months after 
treatment initiation
Mean increase in 
CD4 cell count
Difference in CD4 
cell count increase
Crude
Efavirenz 2476 326 558 232 0
Raltegravir 367 358 618 260 28 (12, 43)
Weighted intent to treat a,b
Efavirenz 2476 349 564 215 0
Raltegravir 367 330 577 247 32 (14, 49)
Weighted per protocol a,c
Efavirenz 2476 349 568 218 0
Raltegravir 367 330 579 248 30 (3, 57)
CNICS: Centers for AIDS Research Network of Integrated Clinical Systems
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Weights were the product of sampling weights (to account for differences in patient characteristics between the study 
population and the US population of people diagnosed with HIV), treatment weights (to account for differences in patient 
characteristics between treatment groups), and censoring weights (to account for differences in time-fixed and time-varying 
characteristics between those censored and those remaining in the study).
b
The intent to treat analysis followed patients from treatment assignment until death, loss to follow-up, or administrative 
censoring.
c
The per protocol analysis censored patients when they changed treatment regimens
Figure A1. 
Proportion achieving initial viral suppression (dotted lines) and viral rebound or death (solid 
lines) among 2486 patients who initiated efavirenz (left) and 368 patients who initiated 
raltegravir (right) in the CNICS between October 12, 2007 and December 31, 2014 (intent to 
treat analysis).
Figure A2. 
Proportion achieving initial viral suppression (dotted lines) and viral rebound or death (solid 
lines) among 2486 patients who initiated efavirenz (left) and 368 patients who initiated 
raltegravir (right) in the CNICS between October 12, 2007 and December 31, 2014 (per 
protocol analysis).
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Probability of being alive and in a state of suppression before viral rebound, Gk(x), in the per 
protocol analysis for 2476 patients who initiated the efavirenz-containing regimen and 367 
patients who initiated the raltegravir-containing regimen in the CNICS between October 12, 
2007 and December 31, 2014 over 30 months of follow-up, weighted to generalize results to 
the US population of people with HIV diagnosed between 2008 and 2014 and to account for 
nonrandom treatment assignment and informative censoring.
Appendix 3. Regimen switching behavior among patients initiating an ART 
regimen containing tenofovir DF, emtricitabine, and raltegravir or efavirenz
Treatment group n Number switched prior to 
suppression
Number switched after 
suppression prior to rebound
Number switched 
after rebound
Efavirenz 2476 385 179 50
Raltegravir 367 24 30 8
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Probability of being alive and in a state of suppression before viral rebound in the intent to 
treat analysis for 2476 patients who initiated the efavirenz-containing regimen and 367 
patients who initiated the raltegravir-containing regimen in the CNICS between October 12, 
2007 and December 31, 2014 over 30 months of follow-up, weighted to generalize results to 
the US population of people with HIV diagnosed between 2008 and 2014 and to account for 
nonrandom treatment assignment and informative censoring.
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